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R E V I E W S
Abstract: The recent introduction of infliximab, a chimeric monoclonal antibody against
tumor necrosis factor-α, has greatly modified the treatment of Crohn’s disease (CD). Data
from the literature show encouraging results after intravenous infusion both for closure of
intestinal or perianal fistulas and for induction and maintenance of remission in patients with
moderate to severe intestinal disease unresponsive to other treatments. However, some
contraindications such as fibrostenosing CD and sepsis have been identified. In addition, the
data on long-term outcomes and safety is still limited. Our initial experience showed that in
selected cases local injection of infliximab is effective in the treatment of complex perianal
disease offering the possibility of using such treatment even in small bowel obstructing disease
with minimal systemic effects. This paper analyzes the state of the use of both intravenous
and local injection of infliximab in patients with CD.
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Pharmacology/mode of action
The pathogenetic mechanisms that underlie the chronic intestinal inflammation of
Crohn’s disease (CD) have been progressively classified since the early 1990s. The
improved knowledge of systemic and local inflammatory cascade allowed the
identification of key mediators of inflammation. Pharmacologic research was
addressed then towards specific biologic drugs interfering with this cascade (Hanauer
2003).
Infliximab is a genetically engineered immunoglobulin 1 (IgG1) murine–human
chimeric monoclonal antibody (Sandborn and Hanauer 1999), which binds with high
affinity to both the soluble and the transmembrane forms of human tumor necrosis
factor-α (TNF-α). Seventy-five percent of the antibody consists of human IgG1 Fc
fragment, the remainder being of murine origin. It is the murine part of the antibody
which can bind human TNF, while the human tract is very important in order to
decrease immunogenicity and for preserving functional immune capacity.
TNF is a key proinflammatory cytokine in CD and in other inflammatory
conditions such as rheumatoid arthritis (Siddiqui and Scott 2005), psoriasis (Kleyn
and Griffiths 2006) and spondylarthropaty (Robinson and Keating 2005) and plays a
central role in amplification of the inflammatory process.
TNF-α is produced mainly by activated macrophages and T lymphocytes, among
other cells, induces other proinflammatory cytokines including interleukin-1 (IL-1)
and IL-6 and enhances leukocyte migration by inducing expression of adhesion
molecules by endothelial cells and leukocytes. It activates leukocytes and induces
acute-phase reactants and metalloproteinases; it also inhibits apoptosis of
inflammatory cells. The number of cells producing TNF greatly increased in the
lamina propria of the bowel in patients with CD (Reinecker et al 1993; Breese et al
1994) and increased concentrations of TNF have been found in the stools of children
with CD (Nicholls et al 1993).
The mechanism of action of infliximab is still not well understood. Its main activity
consists in neutralization of soluble and transmembrane TNF (Mitoma et al 2005) in
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other biological drugs in comparision with etanercept which
can bind only the soluble form of TNF and is therefore less
efficient than infliximab. Research has underlined that the
role of infliximab couldn’t be only in blocking TNF activity
but includes other important functions such as: the
modulation of TNF producing cells by complement fixation
(van den Brande et al 2005); antibody-dependent
cytotoxicity and apoptosis of T lymphocytes and monocytes
caused by the IgG1 Fc portion of the antibody (Scallon et al
1995; Sandborn and Hanauer 1999; Papadakis and Targan
2000); and the down-regulation of other proinflammatory
cytokines. These activities can be demonstrated in biopsy
samples obtained from patients treated with this drug and
by the reduction of cytokine’s concentration in their serum
(Markham and Lamb 2000).
Infliximab can also reduce the number of inflammatory
cells in the sites of inflammation because it decreases the
levels of chemokines and endothelial adhesion molecules,
however it does not produce a generalized suppression of
cellular immune function (Cornillie et al 2001).
Intravenous treatment
Current indications for treatment with infliximab are
refractory luminal CD, steroid-dependent CD, and refractory
fistulizing CD. Such therapy has been showed to be effective
even in systemic manifestation of CD, ankylosing
spondylitis (Jois et al 2006), pyoderma gangrenosum
(Brooklyn et al 2006), chronic uveitis (Hale and Lightman
2006), and metastatic CD (Rispo et al 2004).
Refractory luminal CD
The initial positive experience with infliximab in a single
patient with CD (Derkx et al 1993) led to an open pilot
dose-finding study with 10 patients using 10 mg/kg or 20 mg/
kg doses. Targan and colleagues (1997) conduced then a
placebo controlled trial at doses of 5 mg/kg, 10 mg/kg, and
20 mg/kg in 108 patients with moderately to severely active
CD refractory to conventional therapy. After 4 weeks of
treatment, both clinical response (primary endpoint) and
clinical remission rates were significantly higher in patients
receiving infliximab than placebo recipients (65% vs 17%
and 33% vs 4%, respectively). These patients were then
included in a second study, the f irst on maintenance
evaluation, and were treated with 10 mg/kg or placebo at 0,
12, 20, 28, and 36 weeks. A total of 53% maintained
remission but the majority of patients relapsed between 44
and 48 weeks. Based on these f indings the Authors
concluded that the duration of benefits for infliximab is
approximately 8 weeks.
These results lead to a more comprehensive evaluation
of the clinical benefit of long term maintenance treatment
in the ACCENT I (A Crohn’s disease clinical study
evaluating infliximab in a new long term treatment regimen)
study (Hanauer et al 2002). In this study, repeated treatment
with 5 mg or 10 mg of infliximab was effective in
maintaining remission in patients who had responded to the
initial treatment with no difference between the two dosages
(58% of 573 patients responded by 2 weeks of treatment; at
week 10, 69% responded and 42% reached remission). A
significantly higher number of patients receiving infliximab
were in clinical remission both at week 30 and at week 54.
The study showed that patients will need maintenance
therapy after a loading dose of 5 mg at 0, 2, and 6 weeks
even when treated with concomitant immunosuppression.
In the absence of maintainance therapy, 37% will relapse
by 12 weeks.
Of note, in the ACCENT 1 study, a lower rate of disease-
related hospitalizations occurred in 5 mg/kg and 10 mg/kg
mainteinance treatment groups (23% and 24% respectively
vs 38% in patients treated with episodic therapy). In
addition, a significantly lower rate of abdominal surgical
interventions was required in the first group (2.9% vs 7.4%,
respectively). This data suggests that healing of bowel
lesions obtained after infliximab infusion results in lower
complication rates. The endoscopic ACCENT 1 substudy
(Ruutgers et al 2004) showed that 44% of patients with
colonic ulcers treated with mainteinance doses had complete
mucosal healing after 1 year compared with 18% of patients
treated with episodic 5 mg/kg of infliximab. Patients with
persistent complete healing did not require any
hospitalization or surgery. Finally, the reported incidence
of intestinal obstruction was similar in patients treated with
repeated infusions of infliximab and in those treated with
placebo. While it was not stated in the ACCENT 1 substudy,
to our knowledge, the presence of significant and
symptomatic intestinal stenoses was one of the exclusion
criteria for the study.
Similary, Witthoft and Ludwig (2005) analyzed
continued therapy with infliximab. The patients received
567 infusions (420 re-infusions): 46% had chronic active
CD, 15% fistulas and 38% both symptoms. After treatment,
47% of patients discontinued steroids, and 33% reduced
steroid use; 73% had very good efficacy with the treatment.
De Ridder and colleagues (2004) used infliximab in a
pediatric cohort of 30 patients with refractory CD, with up
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to 30 infusions. Six patients reported a “good, long-term
response”; nearly 53% of all patients experienced an
effective benefit.
Finally, although it has been fully demonstrated that
treatment with infliximab can be effective in obtaining the
healing of mucosal ulcers, this can not modify the thickness
of the intestinal wall in patients with almost fibrotic stenoses
(Figure 1). For this reason, in our opinion, the role of such
therapy in reducing the need for surgery in patients with
symptomatic stenosis has still to be evaluated.
Fistulizing CD
Infliximab has been found to be effective in the management
of entero-cutaneous or perianal fistulae associated with CD.
In the first placebo-controlled trial of 94 patients (Present
et al 1999), mostly with perianal fistulae, closure of at least
half of the fistulas (primary endpoint) occurred in 68% and
complete closure occurred in 55% of the 63 patients
receiving 5 mg/kg or 10 mg/kg of infliximab at 0, 2, and 6
weeks; however 10% developed an abscess at the fistula
site, probably since the skin closure occurred without track
closure. In this study, the success was defined by the Authors
as the absence of perianal secretions, despite “gentle finger
compression”; but this may not necessarily correspond with
healing of the fistula.
Another recent study (Topstad et al 2003) showed that
preinfusional surgical treatment and maintainance
immunosuppression improve the healing rate in fistulizing
anorectal CD. In particular, intravenous infusion of
infliximab following abscess drainage and seton placement
resulted in complete clinical response in 67% of patients
with perianal fistula.
In another study from Mount Sinai Hospital (Toy et al
2000), 79% of the 38 patients treated with intravenous
infusion of infliximab for abdominal or perianal draining
fistulas, had improvement in pain and drainage while 39%
had closure of the fistulas. However, 10 of the 38 patients
needed operation for complete bowel obstruction within 10
weeks after the infusion; four of them had previously known
strictures. The conclusion was that the treatment has to be
used cautiously in patients with possible or documented
strictures.
Another small study by Poritz and colleagues with 28
patients (2002), reported that up to “seventy-three percent
of the patients” with fistulizing CD “either required surgery
or still had open fistulas after therapy”, thus concluding that
the use of infliximab does not abolish the need of surgical
therapy.
Completely different data have however been reported
by Lichtenstein and colleagues (2002) and Weinberg and
colleagues (2002). Lichtenstein evaluated the development
of symptomatic intestinal strictures in patients prospectively
followed in the ACCENT 1 study. No significant increase
was found in the incidence of symptomatic strictures in
patients receiving the higher aggregate amounts of
infliximab. The second study evaluated a large cohort of
patients with known intestinal strictures compared to patients
who received infliximab but did not have strictures. In this
study none of the patients with known strictures had
subsequent complete bowel obstruction. These patients,
however, were found to be less likely to respond to
infliximab, maybe due to end-stage disease that does not
have an important inflammatory component.
The ACCENT II study (Sands et al 2004) showed the
clinical benefit of maintenance treatment with infliximab
in patients with fistulizing CD who had responded to the
induction regimen. In this study patients responders to an
initial dose of 5 mg/kg, were randomized at 14 weeks to 8
weekly intravenous infusions of infliximab 5 mg/kg or
placebo. Patients receiving infliximab experienced a
significantly prolonged time to loss of response (primary
endpoint) compared with that in the placebo group (median
40 vs 14 weeks, p<0.001). At week 54, 36% of patients
treated with infliximab had complete absence of draining
fistulas compared with 19% of those treated with placebo
maintenance. Similarly to ACCENT 1, maintenance
Figure 1 Healed mucosa but still thickened intestinal wall in patient previously
submitted to intravenous infusion of infliximab.  A strictureplasy is performed
due to persisting obstructive symptoms.
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infliximab was associated with signif icant decrease of
hospitalizations and CD-related surgeries. Data from
ACCENT II study were recently analyzed (Sands et al 2006)
to determine whether fistula-related abscess development
is affected by fistula exposure. In this study, patients were
divided in two groups: the first group treated with infliximab
and the second with placebo. Differences in rate of
development of fistulas were analyzed by physical
examination or by imaging procedures. There were no
significant differences between the two groups, with an
incidence of newly developed fistula-related abscess in 15%
of patients treated with infliximab against 19% in the
placebo-treated group. These results suggest that fistulizing
CD is not dependent on infliximab exposure.
Similarly, in a recent study, Lichtenstein and colleagues
(2005), evaluated 282 patients with fistulizing CD, and
found significantly decreased mean hospital stay (0.5 vs
2.5 days), mean number of hospitalizations (11 vs 31), and
decreased number of major surgical procedures in patient
submitted to infliximab maintenance treatment compared
with those who received placebo maintenance. Some
concerns, however, arise after the analysis of the results.
Firstly, the number of fistula-related surgical procedures,
such as drainage and seton placement, extracted from the
overall number of nonmajor surgeries is similar between
placebo and infliximab groups (49 vs 40, respectively). In
addition, mean hospitalization is reported as significantly
lower in infliximab group, but no mention is made about
the type of treatment required during the hospitalization
period. Finally, location of disease is not specified.
Safety issues
Even if the incidence of adverse events is reported as
relatively low in the premarketing trials, recent studies on
larger groups of patients have better defined the safety
aspects of infliximab therapy.
Serious infections
Infectious complications related to impairment of the host
response represent a common concern for all
immunosuppressive therapies. Data from literature show that
the risk of sepsis and opportunistic infections seems to be
higher in patients already submitted to high-dose steroids
and immunosuppressive treatment. The rate of serious
infections in clinical trials on CD, however, is not
significantly higher in patients treated with infliximab
compared with those treated with placebo (6.2 vs 6.8%
respectively) (Rutgers et al 2004). Respiratory and urinary
tract infections are the most common infections reported
(Siddiqui and Scott 2005).
However, a higher need for antibiotic therapy for
infectious complications in patients receiving infliximab
versus placebo group (32% vs 22%, respectively) is reported
(Remicade PI 2001; Warris et al 2001). Preliminary data
from the START trial in patients with rheumatoid arthritis
have shown the risk of serious infections with infliximab
3mg/kg to be similar to placebo, while 10 mg/kg was
associated with a higher relative risk than placebo
(Westhovens et al 2005). Some cases of opportunistic
infections, such as aspergillosis and listeriosis have been
reported (Remicade PI 2001; Alderson et al 2005). In
addition, a large cohort study (Colombel et al 2004)
evaluating short and long-term safety of infliximab in 500
consecutive patients with CD treated at the Mayo Clinic
showed that infliximab-related infections occurred in 8.2%
of patients. Twenty patients had serious infections, including
2 with fatal sepsis, 2 with fatal pneumonia, 6 with viral
infections, 2 with intraabdominal abscess, and one cellulitis
and histoplasmosis, respectively. Colombel and colleagues
concluded that even if infliximab is generally well tolerated,
“clinicians must be vigilant for the occurrence of infrequent
but serious events”.
Malignancies
Long-term follow-up is needed to assess whether or not there
is an increased risk of lymphoma or other malignancies. To
date, non-Hodgkin lymphoma has been reported in only 3
patients treated for CD and 4 for rheumatoid arthritis
(Bickston et al 1999; Remicade PI 2001; Sachmechian et al
2001), and all events occurred in patients already submitted
to concomitant immunosuppression. However, the well
known trend of CD patients to develop lymphoma and the
high rate of lymphomas in immunosuppressed population
justify the need for epidemiologic studies to investigate this
likely association.
The risk of other malignancies does not seem to be
higher. Kane and Reddy (2004) analyzed the prevalence of
abnormal Pap smears in 68 women with CD treated with
infliximab. There were no cancers and the risk of an
abnormal Pap smear was not related to the use of infliximab.
However, Chen and colleagues (2006) recently reported a
case of hepatocellular carcinoma occurring in a noncirrhotic
CD patient who had been treated with both azathioprine
and infliximab. Whether infliximab directly or indirectly
enhanced susceptibility to the development of hepatocellular
carcinoma in this patient is not known, but it is possible
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that infliximab may be a contributing factor in its
pathogenesis.
Neurological adverse events
Infliximab has been associated with rare cases of new onset
or exacerbation of clinical symptoms or radiographic
evidence of demyelization disorders such as multiple
sclerosis and optic neuritis (Wiendl and Hohlfeld 2002;
Thomas et al 2004; Enayati et al 2005).
A recent study on 7988 patients with CD and 12 185
with ulcerative colitis showed a higher incidence of
demyelinating diseases among patients with inflammatory
bowel disease. Further studies are needed to clarify the real
effect of anti-TNF-α therapy (Gupta et al 2005).
Polmonary adverse events
Reactivation of latent tuberculosis is a frightening risk of
anti-TNF-α therapy. Active tuberculosis has been found in
350 out of 400 000 patients treated. Most cases occurred
within 2 months after first infusion (Keane et al 2001).
Tubercolin skin testing and chest radiograph in patients with
positive skin test are recommended (ATS 2000) to initiate
appropriate antitubercular therapy before infliximab
treatment.
Infusion-related events
Infusion-related events are common within 1–2 hours after
an infusion in approximately 20% of patients. The most
common events are fever and chills, cardiopulmonary
symptoms, and urticaria/pruritus (Centocor 2005a, 2005b).
Serious events, such as anaphylaxis occur in <1% of
infliximab recipients. These adverse events can be controlled
with drugs (antihistamines or steroids), by slowing down
the infusion rate or by discontinuation of infliximab.
Repeated infusions are not associated with an increase in
the incidence of reactions.
Immunogenic reactions
Treatment with infliximab could be complicated by
production of autoantibodies and antibodies to drug.
The formation of antibodies anti-infliximab (ATI) has
been reported in 13% of patients treated in clinical trials
(Remicade PI 2001). However, the detection of antibodies
depends on the sensitivity and the specifications of the essay
used (Rutgeers et al 2005). Baert and colleagues (2003)
found antibody to infliximab (ATI) in 61% of patients, while
Farrel and colleagues (2003) reported an incidence of 36%,
using the same essay. These studies demonstrated that the
formation of ATI is associated with the occurrence of
infusion reactions and with shorter duration of response,
while it was decreased by concomitant immunosuppressive
therapy.
Vermeire and colleagues (2003) found an incidence of
56.8% after 24 months of treatment, with antibodies still
present one year after last infusion. In two patients an
infliximab-related lupus eritematosus occurred. Vermiere
reported an association between formation of antibodies and
female gender.
Acute reactions are generally easily managed by
interrupting infusion and administration of hydrocortisone.
Prophylactic anthistamine and hydrocortisone can prevent
further reactions.
Severe serum sickness-like reactions, with fever, rash,
headache sore throat, myalgia, facial edema and dysphagia,
are often associated with episodic treatment, especially after
a long drug-free period (Kugathasan et al 2002; Vermeire
et al 2003). Symptoms are treated with intravenous or oral
steroids at high doses.
Local treatment
To minimize the risks and to allow the treatment with
infliximab even in patients with perianal CD and associated
bowel strictures, Lichtiger (2001) had recently proposed the
local injection of anti-TNF-a as an alternative to systemic
infusion. The rationale for using such technique is based on
the evidence, as discussed above, that clinical efficacy of
infliximab is due to local anti-inflammatory and
immunomodulatory effects in the bowel mucosa, by means
of down-regulation of the adhesion molecules within the
lamina propria (Cornillie et al 2001). Hence, infiltration of
the antibody through the mucosal barrier should enhance
its effectiveness.
Lichtiger (2001) reported his experience with 9 patients
with mild to moderate perianal disease refractory to
antibiotics or 6-MP, treated with a circumferential and
intrafistulous injection of infliximab at 0, 4, and 7 weeks.
He reported complete healing of the fistula tract in 50% of
patients within 3 weeks; 33% had a partial response and
17% did not respond to the treatment. Based on this
experience, we have started using this treatment with a
modified technique (Poggioli et al 2005), which may
contribute to improved results. Specifically, the injection
of the drug at the internal orifice allowed the closure of the
entire fistulous tract, avoiding false closures limited to the
external opening which could lead to new abscess
development.
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All patients were treated under general or spinal
anaesthesia. Visual inspection, palpation and exploration
with probes were performed in order to identify all the
fistulous tracts and abscesses; purulent material was drained
and the fistula tracts curetted. If necessary, necrotic and
inflamed tissues were excised at each operation. Draining
setons previously placed in the fistulous tract were removed
at the time of the first infusion.
An injection of 15 mg to 21 mg of infliximab, diluted in
10–14 cc of 5% glucose solution, was then carried out
circumferentially at the level of the internal orifice and
subsequently in the wall of the fistula tract up to the external
orifice. This was done in all fistulas. For all patients we
scheduled at least six treatments at 0, 4, 8, 12, 16, and 20
weeks, respectively.
At each subsequent treatment, before infliximab
injection, the eff icacy of the treatment was assessed
separately by two of the Authors (Poggioli and Laureti) by
means of a complete examination of the perineum, using a
4 grade personal score (PS) system as follows: grade 1 =
unchanged; grade 2 = sepsis control, but persisting pus
discharge from fistulas; grade 3 = no pus discharge, no
granulation tissue; grade 4 = closure with scar tissue (tested
with probe examination).
We have treated 31 patients to date with a diagnosis of
CD and complex perianal fistulas (Sandborn et al 2003)
with local injection of infliximab.
The indication for treatment was the presence of complex
perianal disease in which the fistula was not controllable
by means of medical therapy, seton drainage, fistulotomy,
or removal of the fistula tract.
Mean follow-up was 40.6 months (range 3–54 months).
No major adverse events were reported. Five patients
reported a sensation of heaviness at the injection site for 5–
6 days.
Forty-four patients had concomitant small bowel disease.
Among them, 38 patients had coexisting intestinal
fibrostenosing CD and were therefore not suitable for
intravenous infliximab. In this group, 79.0% healed their
fistulas after 6 to 14 injections, reaching grade 4 of PS. Seven
patients reached grade 3 after 3 to 5 infusion and are still in
treatment. One patient developed recurrent fistula 14 months
after last injection and has been recently submitted to
redrainage and 2 local injections of infliximab.
Six additional patients with small bowel disease not
responsive to previous treatment with intravenous infliximab
underwent local injection; only three of them had complete
closure of the fistula tracts (grade 4).
Five patients had associated severe colo-proctitis: three
had poor results (grade 2) and underwent total abdominal
colectomy with Brooke ileostomy and Hartmann’s pouch.
The remaining 2 patients reached grade 3 of the score after
7 and 9 injections respectively.
The results from our pilot study show that local injection
of infliximab is safe and feasible. There were no major
adverse events and only one third of the patients reported
minimal perianal discomfort after the treatment.
Although the analysis of the results and of the value of
our conclusions is limited by the small sample size and the
absence of a control group, our experience suggests that
local injection could be effective in patients with aggressive
perianal disease not treatable with surgery alone and unable
to receive intravenous infusion of infliximab. Certainly,
further experience with prospective studies is needed, using
controls which include no infliximab as well as placebo
injection. Moreover, further studies are required in order to
evaluate the need of a maintenance treatment once grade 4
of PS is obtained.
Finally, the assessment of the success rate is
controversial. In fact, the variety of results reported in the
literature is probably due to the lack of agreement between
the investigators on clinical assessment. Recently, a
misclassification of patients with perianal disease using
examination under anesthesia (EUA) alone up to 10% was
reported (Spencer et al 1998; Beets-Tan et al 2001; van
Assche et al 2003); in fact, apparent clinical closure of
fistulas sometimes is associated with ultrasound evidence
of persistence (Poritz et al 2002).
The usefulness of association of magnetic resonance
imaging with EUA has been recently emphasized (Sandborn
et al 2003). As highlighted by some authors (Schwartz et al
2001; van Assche et al 2003) this technique seems promising
since it offers objective criteria of “true” fistula healing,
after intravenous infusion and local injection of infliximab;
the experience with this procedure, however is limited and
needs skilled radiologists in order to rule out false closures
(Bell et al 2003).
Conclusions: guidelines for the use
of infliximab
Based on data available to date in the literature, intravenous
therapy with infliximab is indicated in selected cases, as
follows:
• Patients with moderate to severe CD who demonstrate
persisting symptoms or intolerance to conventional
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therapy (steroids and immunosuppressors), or are unable
to tolerate such therapies.
• Patients with fistulizing CD, entero-cutaneous, perianal,
entero-vesical or entero-vaginal.
The initial dose with three infusions, at weeks 0, 2, and
6 allows obtaining a higher remission rate. Patients who do
not responde to three infusions should not receive further
infliximab administration.
If no contraindications exist, patients should receive
concomitant immunosuppressive therapy in order to reduce
formation of antibodies and likelihood of reactions and
obtain higher response rates. Concomitant
immunosuppression is indicated even in those patients who
did not respond to previous treatment.
Regular repeat doses every 8 weeks are effective in
maintaining clinical response after induction; although
further studies are required to obtain more definitive data
about the safety of long-term treatment with infliximab.
Absolute contraindications are:
• Patients with known active infection.
• Patients with central nervous system demyelinating
syndromes.
• Patients with class III–IV congestive heart failure.
• Underlying abscess.
• Positive TB skin test.
Infliximab should be used with caution in patients with:
• Significant intestinal obstructive symptoms or
documented fibrotic intestinal stenosis without clinical
or biochemical evidence of CD activity.
• Current or previous malignancies.
• Pregnancy or lactation.
Finally, local injection of infliximab for the treatment
of perianal CD in selected cases is safe and feasible. This
treatment could represent an effective option for those
patients with perianal f istulas who cannot undergo
intravenous infliximab treatment especially if there is
associated stenosing ileal CD.
However, further randomized studies are needed to
evaluate the effectiveness and the correct indications for
this technique.
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